Oral Contraceptives in Polycystic Ovary Syndrome: Risk-Benefit Assessment

 

 Buy Article Permissions and Reprints

ABSTRACT

Combined oral contraceptive pills (OCPs) have been a key component of the chronic treatment of polycystic ovary syndrome (PCOS) by improving androgen excess and regulating menstrual cycles. Earlier epidemiologic studies with second- and third-generation OCPs in the general population have raised important questions regarding long-term cardiometabolic effects of these agents. In PCOS, there are only a few short-term studies with contradictory results evaluating potential adverse effects of OCPs on cardiovascular risk factors and glucose homeostasis. These studies included a small number of participants and did not take into account several confounding factors that might influence the outcome. Nevertheless, limited available data support the benefits of long-term OCP use in PCOS. By contrast, solid evidence for cardiometabolic adverse outcome with the use of these agents, especially with newer OCPs containing antiandrogenic progestins, is lacking. More studies are needed to resolve controversies regarding the safety of long-term OCP use in PCOS. Meanwhile, assessment of each PCOS patient's personal cardiometabolic risk profile should be an essential component of the evaluation before prescribing OCPs and also during follow-up.

REFERENCES

• 1 Ehrmann D A. Polycystic ovary syndrome.  N Engl J Med. 2005;  352 1223-1236
  CrossrefPubMedGoogle Scholar
• 2 Yildiz B O. Recent advances in the treatment of polycystic ovary syndrome.  Expert Opin Investig Drugs. 2004;  13 1295-1305
  CrossrefPubMedGoogle Scholar
• 3 Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome.  Hum Reprod Update. 2005;  11 277-291
  CrossrefPubMedGoogle Scholar
• 4 Diamanti-Kandarakis E, Baillargeon J P, Iuorno M J, Jakubowicz D J, Nestler J E. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills.  J Clin Endocrinol Metab. 2003;  88 1927-1932
  CrossrefPubMedGoogle Scholar
• 5 Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis.  Hum Reprod. 2007;  22 317-322
  PubMedGoogle Scholar
• 6 Petitti D B. Clinical practice. Combination estrogen-progestin oral contraceptives.  N Engl J Med. 2003;  349 1443-1450
  CrossrefPubMedGoogle Scholar
• 7 Sitruk-Ware R. New progestagens for contraceptive use.  Hum Reprod Update. 2006;  12 169-178
  PubMedGoogle Scholar
• 8 Stanczyk F Z. All progestins are not created equal.  Steroids. 2003;  68 879-890
  CrossrefPubMedGoogle Scholar
• 9 Elger W, Beier S, Pollow K, Garfield R, Shi S Q, Hillisch A. Conception and pharmacodynamic profile of drospirenone.  Steroids. 2003;  68 891-905
  CrossrefPubMedGoogle Scholar
• 10 Boyce J, Fawcett J W, Noall E W. Coronary thrombosis and Conovide.  Lancet. 1963;  1 111
  PubMedGoogle Scholar
• 11 Jick H, Dinan B, Herman R, Rothman K J. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors.  JAMA. 1978;  240 2548-2552
  CrossrefPubMedGoogle Scholar
• 12 Stadel B V. Oral contraceptives and cardiovascular disease (first of two parts).  N Engl J Med. 1981;  305 612-618
  PubMedGoogle Scholar
• 13 Walker I D. Exogenous sex hormones and thrombophilia.  Obstet Gynecol Clin North Am. 2006;  33 467-479 x
  CrossrefPubMedGoogle Scholar
• 14 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception . Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study.  Lancet. 1995;  346 1575-1582
  PubMedGoogle Scholar
• 15 Crook D. Do different brands of oral contraceptives differ in their effects on cardiovascular disease?.  Br J Obstet Gynaecol. 1997;  104 516-520
  PubMedGoogle Scholar
• 16 Khader Y S, Rice J, John L, Abueita O. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis.  Contraception. 2003;  68 11-17
  CrossrefPubMedGoogle Scholar
• 17 Baillargeon J P, McClish D K, Essah P A, Nestler J E. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis.  J Clin Endocrinol Metab. 2005;  90 3863-3870
  CrossrefPubMedGoogle Scholar
• 18 Merz C N, Johnson B D, Berga S, Braunstein G, Reis S E, Bittner V. Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation.  Fertil Steril. 2006;  85 1425-1431
  CrossrefPubMedGoogle Scholar
• 19 Sidney S, Siscovick D S, Petitti D B et al.. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies.  Circulation. 1998;  98 1058-1063
  PubMedGoogle Scholar
• 20 Schwartz S M, Siscovick D S, Longstreth Jr W T et al.. Use of low-dose oral contraceptives and stroke in young women.  Ann Intern Med. 1997;  127 596-603
  CrossrefPubMedGoogle Scholar
• 21 Petitti D B, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel H K. Stroke in users of low-dose oral contraceptives.  N Engl J Med. 1996;  335 8-15
  CrossrefPubMedGoogle Scholar
• 22 Schwingl P J, Ory H W, Visness C M. Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States.  Am J Obstet Gynecol. 1999;  180 241-249
  CrossrefPubMedGoogle Scholar
• 23 Godsland I F. The influence of female sex steroids on glucose metabolism and insulin action.  J Intern Med Suppl. 1996;  738 1-60
  PubMedGoogle Scholar
• 24 Godsland I F, Crook D, Simpson R et al.. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.  N Engl J Med. 1990;  323 1375-1381
  CrossrefPubMedGoogle Scholar
• 25 Godsland I F, Walton C, Felton C, Proudler A, Patel A, Wynn V. Insulin resistance, secretion, and metabolism in users of oral contraceptives.  J Clin Endocrinol Metab. 1992;  74 64-70
  CrossrefPubMedGoogle Scholar
• 26 Watanabe R M, Azen C G, Roy S, Perlman J A, Bergman R N. Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors.  J Clin Endocrinol Metab. 1994;  79 1277-1283
  CrossrefPubMedGoogle Scholar
• 27 Troisi R J, Cowie C C, Harris M I. Oral contraceptive use and glucose metabolism in a national sample of women in the United States.  Am J Obstet Gynecol. 2000;  183 389-395
  CrossrefPubMedGoogle Scholar
• 28 Kim C, Siscovick D S, Sidney S, Lewis C E, Kiefe C I, Koepsell T D. Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA Study. Coronary Artery Risk Development in Young Adults.  Diabetes Care. 2002;  25 1027-1032
  CrossrefPubMedGoogle Scholar
• 29 Rimm E B, Manson J E, Stampfer M J et al.. Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women.  Diabetologia. 1992;  35 967-972
  CrossrefPubMedGoogle Scholar
• 30 Chasan-Taber L, Willett W C, Stampfer M J et al.. A prospective study of oral contraceptives and NIDDM among U.S. women.  Diabetes Care. 1997;  20 330-335
  CrossrefPubMedGoogle Scholar
• 31 Kjos S L, Peters R K, Xiang A, Thomas D, Schaefer U, Buchanan T A. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus.  JAMA. 1998;  280 533-538
  CrossrefPubMedGoogle Scholar
• 32 Grimes D A, Economy K E. Primary prevention of gynecologic cancers.  Am J Obstet Gynecol. 1995;  172 227-235
  CrossrefPubMedGoogle Scholar
• 33 The ESHRE Capri Workshop Group . Noncontraceptive health benefits of combined oral contraception.  Hum Reprod Update. 2005;  11 513-525
  CrossrefPubMedGoogle Scholar
• 34 Gallo M F, Lopez L M, Grimes D A, Schulz K F, Helmerhorst F M. Combination contraceptives: effects on weight.  Cochrane Database Syst Rev. 2006;  CD003987
  PubMedGoogle Scholar
• 35 World Health Organization .Medical eligibility criteria for contraceptive use. Third edition. 2004 Available at: http://www.who.int/reproductive-health/publications/mec/index.htm
  Google Scholar
• 36 Cerel-Suhl S L, Yeager B F. Update on oral contraceptive pills.  Am Fam Physician. 1999;  60 2073-2084
  PubMedGoogle Scholar
• 37 Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.  Fertil Steril. 2002;  77 919-927
  CrossrefPubMedGoogle Scholar
• 38 Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome.  Hum Reprod. 2001;  16 36-42
  CrossrefPubMedGoogle Scholar
• 39 Belisle S, Love E J. Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study.  Fertil Steril. 1986;  46 1015-1020
  PubMedGoogle Scholar
• 40 Miller J A, Wojnarowska F T, Dowd P M et al.. Anti-androgen treatment in women with acne: a controlled trial.  Br J Dermatol. 1986;  114 705-716
  PubMedGoogle Scholar
• 41 Mowszowicz I, Wright F, Vincens M et al.. Androgen metabolism in hirsute patients treated with cyproterone acetate.  J Steroid Biochem. 1984;  20 757-761
  CrossrefPubMedGoogle Scholar
• 42 Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review.  Mol Cell Endocrinol. 2004;  217 255-261
  CrossrefPubMedGoogle Scholar
• 43 Guido M, Romualdi D, Giuliani M et al.. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.  J Clin Endocrinol Metab. 2004;  89 2817-2823
  CrossrefPubMedGoogle Scholar
• 44 Palep-Singh M, Mook K, Barth J, Balen A. An observational study of Yasmin in the management of women with polycystic ovary syndrome.  J Fam Plann Reprod Health Care. 2004;  30 163-165
  CrossrefPubMedGoogle Scholar
• 45 Azziz R, Waggoner W T, Ochoa T, Knochenhauer E S, Boots L R. Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama.  Fertil Steril. 1998;  70 274-278
  CrossrefPubMedGoogle Scholar
• 46 Hardiman P, Pillay O C, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma.  Lancet. 2003;  361 1810-1812
  CrossrefPubMedGoogle Scholar
• 47 Apridonidze T, Essah P A, Iuorno M J, Nestler J E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2005;  90 1929-1935
  CrossrefPubMedGoogle Scholar
• 48 Ehrmann D A, Liljenquist D R, Kasza K, Azziz R, Legro R S, Ghazzi M N. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2006;  91 48-53
  CrossrefPubMedGoogle Scholar
• 49 Legro R S. Polycystic ovary syndrome and cardiovascular disease: a premature association?.  Endocr Rev. 2003;  24 302-312
  PubMedGoogle Scholar
• 50 Orio F, Palomba S, Colao A. Cardiovascular risk in women with polycystic ovary syndrome.  Fertil Steril. 2006;  86(Suppl 1) S20-S21
  PubMedGoogle Scholar
• 51 Christian R C, Dumesic D A, Behrenbeck T, Oberg A L, Sheedy II P F, Fitzpatrick L A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2003;  88 2562-2568
  CrossrefPubMedGoogle Scholar
• 52 Rizzo M, Rini G B, Carmina E. Androgen excess and cardiovascular risk.  Minerva Endocrinol. 2007;  32 67-71
  PubMedGoogle Scholar
• 53 Chang W Y, Knochenhauer E S, Bartolucci A A, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups.  Fertil Steril. 2005;  83 1717-1723
  CrossrefPubMedGoogle Scholar
• 54 Yildiz B O, Gedik O. Insulin resistance in polycystic ovary syndrome: hyperandrogenemia versus normoandrogenemia.  Eur J Obstet Gynecol Reprod Biol. 2001;  100 62-66
  CrossrefPubMedGoogle Scholar
• 55 Solomon C G, Hu F B, Dunaif A et al.. Menstrual cycle irregularity and risk for future cardiovascular disease.  J Clin Endocrinol Metab. 2002;  87 2013-2017
  CrossrefPubMedGoogle Scholar
• 56 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.  Endocr Rev. 1997;  18 774-800
  CrossrefPubMedGoogle Scholar
• 57 Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus.  Fertil Steril. 2002;  77 1095-1105
  CrossrefPubMedGoogle Scholar
• 58 Azziz R, Carmina E, Dewailly D et al.. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.  J Clin Endocrinol Metab. 2006;  91 4237-4245
  Google Scholar
• 59 Ehrmann D A, Barnes R B, Rosenfield R L, Cavaghan M K, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.  Diabetes Care. 1999;  22 141-146
  CrossrefPubMedGoogle Scholar
• 60 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.  J Clin Endocrinol Metab. 1999;  84 165-169
  CrossrefPubMedGoogle Scholar
• 61 Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome.  Int J Gynaecol Obstet. 2001;  75 177-184
  CrossrefPubMedGoogle Scholar
• 62 Gambineri A, Pelusi C, Manicardi E et al.. Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors.  Diabetes. 2004;  53 2353-2358
  CrossrefPubMedGoogle Scholar
• 63 Norman R J, Masters L, Milner C R, Wang J X, Davies M J. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.  Hum Reprod. 2001;  16 1995-1998
  CrossrefPubMedGoogle Scholar
• 64 American Diabetes Association . Screening for diabetes.  Diabetes Care. 2002;  25 S21-S24
  CrossrefPubMedGoogle Scholar
• 65 Korytkowski M T, Mokan M, Horwitz M J, Berga S L. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 1995;  80 3327-3334
  CrossrefPubMedGoogle Scholar
• 66 Nader S, Riad-Gabriel M G, Saad M F. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women.  J Clin Endocrinol Metab. 1997;  82 3074-3077
  CrossrefPubMedGoogle Scholar
• 67 Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson P O. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome.  Hum Reprod. 1998;  13 2706-2711
  CrossrefPubMedGoogle Scholar
• 68 Vrbikova J, Stanicka S, Dvorakova K et al.. Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjunction with peroral cyproterone acetate in women with polycystic ovary syndrome.  Eur J Endocrinol. 2004;  150 215-223
  CrossrefPubMedGoogle Scholar
• 69 Cagnacci A, Paoletti A M, Renzi A et al.. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel.  J Clin Endocrinol Metab. 2003;  88 3621-3625
  CrossrefPubMedGoogle Scholar
• 70 Morin-Papunen L C, Vauhkonen I, Koivunen R M, Ruokonen A, Martikainen H K, Tapanainen J S. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.  J Clin Endocrinol Metab. 2000;  85 3161-3168
  CrossrefPubMedGoogle Scholar
• 71 Armstrong V L, Wiggam M I, Ennis C N et al.. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.  QJM. 2001;  94 31-37
  CrossrefPubMedGoogle Scholar
• 72 Cibula D, Sindelka G, Hill M, Fanta M, Skrha J, Zivny J. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin.  Hum Reprod. 2002;  17 76-82
  PubMedGoogle Scholar
• 73 Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.  Hum Reprod. 2002;  17 1729-1737
  PubMedGoogle Scholar
• 74 Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen J S. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.  J Clin Endocrinol Metab. 2003;  88 148-156
  PubMedGoogle Scholar
• 75 Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.  J Clin Endocrinol Metab. 2003;  88 4116-4123
  CrossrefPubMedGoogle Scholar
• 76 Cibula D, Fanta M, Vrbikova J et al.. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.  Hum Reprod. 2005;  20 180-184
  PubMedGoogle Scholar
• 77 Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero J I, Martinez-Bermejo E, Lasuncion M A, Escobar-Morreale H F. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.  J Clin Endocrinol Metab. 2007;  92 2453-2461
  CrossrefPubMedGoogle Scholar
• 78 Falsetti L, Pasinetti E. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.  Acta Obstet Gynecol Scand. 1995;  74 56-60
  CrossrefPubMedGoogle Scholar
• 79 Pasquali R, Gambineri A, Anconetani B et al.. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment.  Clin Endocrinol (Oxf). 1999;  50 517-527
  CrossrefPubMedGoogle Scholar
• 80 Sharma S T, Nestler J E. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers.  Best Pract Res Clin Endocrinol Metab. 2006;  20 245-260
  CrossrefPubMedGoogle Scholar
• 81 Knowler W C, Barrett-Connor E, Fowler S E et al.. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
  CrossrefPubMedGoogle Scholar
• 82 Macfarlane D P, Paterson K R, Fisher M. Oral antidiabetic agents as cardiovascular drugs.  Diabetes Obes Metab. 2007;  9 23-30
  PubMedGoogle Scholar
• 83 Rautio K, Tapanainen J S, Ruokonen A, Morin-Papunen L C. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.  Eur J Endocrinol. 2005;  152 269-275
  CrossrefPubMedGoogle Scholar
• 84 Costello M F, Shrestha B, Eden J, Johnson N P, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review.  Hum Reprod. 2007;  22 1200-1209
  CrossrefPubMedGoogle Scholar

Bulent O YildizM.D. 

Hacettepe University, School of Medicine, Department of Internal Medicine

Endocrinology and Metabolism Unit, Hacettepe, Ankara, 06100, Turkey

Email: yildizbo@yahoo.com